Posts by Mourabit Halima

Renal cancer is a common malignancy of the urinary system. For localized and locally advanced renal cancer without distant or extraregional lymph node metastases, surgical removal of the tumor or the affected kidney remains the primary treatment. Recent advances in targeted therapy and immunotherapy have expanded the options for perioperative treatment of renal cancer. In 2024, this field saw significant breakthroughs, and Dr. Liangyou Gu from the Chinese PLA General Hospital shared the latest research developments.

From November 14 to 17, 2024, the Cellular Therapy and Immunotherapy Conference (CTI) was held in Hangzhou, China, bringing together global experts, scholars, and industry leaders in cellular and immunotherapy.…

In recent years, immunotherapy drugs, particularly PD-1/PD-L1 inhibitors, have gradually expanded from being used in later-line treatments to frontline therapy for non-small cell lung cancer (NSCLC). Perioperative immunotherapy has become a major focus in the field, with numerous breakthroughs reshaping the treatment landscape for operable NSCLC patients. However, challenges remain in patient selection, treatment regimens, and comprehensive perioperative management. As the year comes to an end, Oncology Frontier invited Dr. Changli Wang from Tianjin Medical University Cancer Institute and Hospital to review the progress and discuss the future prospects of perioperative immunotherapy for NSCLC in 2024.

At the end of 2024, the 2025 Essentials of CBCS & CSOBO Breast Cancer Diagnosis and Treatment Guidelines (hereafter referred to as the "New Little Red Book") was officially released during the 16th Shanghai Breast Cancer Symposium and Annual Meeting of the Shanghai Anti-Cancer Association Breast Cancer Committee. This updated edition provides fresh guidance for clinical breast cancer practices.